FINWIRES · TerminalLIVE
FINWIRES

D.R. Horton Faces Margin, Volume Pressure as Incentive Costs Rise, Oppenheimer Says

By

D.R. Horton (DHI) may face near-term profitability pressure and weaker volumes as rising incentive costs and macro headwinds weigh on its outlook, Oppenheimer said Thursday in a report.

Oppenheimer cut estimates ahead of fiscal Q2, citing expected margin pressure in H2 and a lower fiscal 2026 closings forecast. Demand "remained steady" through late March, suggesting results could track close to company expectations, the report said.

Gross margin is projected to decline sequentially in Q3, diverging from Wall Street expectations for a modest increase, as "elevated mortgage rates" continue to drive promotional activity, Oppenheimer said. Even if incentives stay "flat," margin compression is likely as cost pressures, including "lot cost inflation," persist, the report said.

Closings could fall short of guidance if the company prioritizes "margin over pace" amid softer demand and slowing community growth, though lower inventory levels may give D.R. Horton flexibility to manage volumes and support margins, the report said.

D.R. Horton has a "less attractive" risk-reward profile tied to its "interest-rate-sensitive customer base," limited buyer diversity and rental-business volatility, the report said.

Oppenheimer has a perform rating on D.R. Horton stock.

Q2 results are due Tuesday.

Price: $144.89, Change: $+0.69, Percent Change: +0.48%

Related Articles

Wire

Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application

Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.

$SVRA
Wire

Euroseas Extends EM Kea Charter for Three Years at Higher Daily Rate

Euroseas (ESEA) extended a charter contract for its feeder containership EM Kea by three years at a gross daily rate of $30,000.The charter is set to begin on July 14 and reflects nearly a 60% increase over the vessel's current rate, the company said Wednesday in a statement.Euroseas expects the charter to generate about $22.5 million in EBITDA over the minimum contracted period.The company's shares fell 2% in after-hours trading.

$ESEA
Wire

Voyager Wins NASA Order for Seventh Private Astronaut Mission to International Space Station

Voyager Technologies (VOYG) said late Wednesday it has signed an order with National Aeronautics and Space Administration for the seventh private astronaut mission to the International Space Station, with a launch planned no earlier than 2028.The mission, dubbed VOYG-1, supports NASA's strategy to shift low-Earth orbit operations to the private sector by enabling commercial partners to deliver human spaceflight services, the company said.

$VOYG